MARKET

ARAV

ARAV

Aravive Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.070
+0.020
+0.49%
Closed 19:52 09/22 EDT
OPEN
4.050
PREV CLOSE
4.050
HIGH
4.100
LOW
3.950
VOLUME
73.64K
TURNOVER
--
52 WEEK HIGH
9.95
52 WEEK LOW
3.630
MARKET CAP
84.31M
P/E (TTM)
-2.3871
1D
5D
1M
3M
1Y
5Y
Aravive to Participate in Fireside Chat at Cantor Fitzgerald Virtual Global Healthcare Conference
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Ch...
GlobeNewswire · 6d ago
Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investment Conference
HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of A...
GlobeNewswire · 09/01 11:00
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 207 companies hit new 52-week lows.
Benzinga · 08/16 14:12
BRIEF-Aravive Announces First Patient Dosed In Phase 1B/2 Clinical Trial Of AVB-500
reuters.com · 08/09 11:12
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
Trial to Evaluate AVB-500 as a First-Line Treatment in Combination with Gemcitabine and Nab-Paclitaxel Continues Expansion of AVB-500 in Multiple Oncology Indications and Combinations HOUSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), ...
GlobeNewswire · 08/09 11:00
--Piper Sandler Adjusts Aravive's Price Target to $18 From $20, Maintains Overweight Rating
MT Newswires · 08/06 13:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARAV. Analyze the recent business situations of Aravive Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARAV stock price target is 22.00 with a high estimate of 26.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 89
Institutional Holdings: 8.74M
% Owned: 42.20%
Shares Outstanding: 20.71M
TypeInstitutionsShares
Increased
16
600.66K
New
9
312.34K
Decreased
18
1.22M
Sold Out
19
273.36K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.30%
Pharmaceuticals & Medical Research
-0.11%
Key Executives
Non-Executive Chairman/Independent Director
Fredric Eshelman
President/Chief Executive Officer/Director
Gail McIntyre
Chief Financial Officer
Vinay Shah
Other
Reshma Rangwala
Director
Peter Ho
Director
John Hohneker
Director
Sigurd Kirk
Independent Director
Amato Giaccia
Independent Director
Michael Rogers
Independent Director
Eric Zhang
No Data
About ARAV
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases including cancer and fibrosis. Its lead product candidate, AVB-500, is an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment and decreased survival. The Company is evaluating AVB-500 in a registrational Phase III trial in platinum resistant ovarian cancer, a Phase Ib/2 trial in second line plus, clear cell renal cell carcinoma (ccRCC), and a Phase Ib/2 trial in first-line treatment of pancreatic adenocarcinoma.

Webull offers kinds of Aravive Inc stock information, including NASDAQ:ARAV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARAV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARAV stock methods without spending real money on the virtual paper trading platform.